Isomorphic Labs Reportedly Seeking Funding at $40B–$50B Valuation

Alphabet's AI drug discovery spin-off, Isomorphic Labs, is reportedly in early negotiations to secure a new funding round at a valuation between $40 billion and $50 billion. This comes shortly after the company completed a $2.1 billion Series B funding round in May. A potential $40 billion-plus valuation reflects immense investor enthusiasm for applying frontier AI technologies to biopharmaceutical research. If completed, it would solidify Isomorphic Labs' position as one of the most valuable private AI enterprises in the world. The company is led by Demis Hassabis, co-recipient of the 2024 Nobel Prize in Chemistry and CEO of Google DeepMind. However, despite rapid advancements in AI predictive modeling, therapeutic candidates generated by these platforms still must undergo multi-year clinical trials to prove efficacy and safety.